JP2012095641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012095641A5 JP2012095641A5 JP2011160400A JP2011160400A JP2012095641A5 JP 2012095641 A5 JP2012095641 A5 JP 2012095641A5 JP 2011160400 A JP2011160400 A JP 2011160400A JP 2011160400 A JP2011160400 A JP 2011160400A JP 2012095641 A5 JP2012095641 A5 JP 2012095641A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- substitution
- vivo
- group
- glycosylation site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 27
- 238000001727 in vivo Methods 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 230000004988 N-glycosylation Effects 0.000 claims 15
- 230000004048 modification Effects 0.000 claims 14
- 238000012986 modification Methods 0.000 claims 14
- 208000032843 Hemorrhage Diseases 0.000 claims 8
- 208000034158 bleeding Diseases 0.000 claims 8
- 230000000740 bleeding effect Effects 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 230000013595 glycosylation Effects 0.000 claims 6
- 238000006206 glycosylation reaction Methods 0.000 claims 6
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000031220 Hemophilia Diseases 0.000 claims 4
- 208000009292 Hemophilia A Diseases 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000002271 resection Methods 0.000 claims 2
- 102220253478 rs1553261891 Human genes 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 102220595361 Anamorsin_A34E_mutation Human genes 0.000 claims 1
- 102220594400 HLA class I histocompatibility antigen, C alpha chain_D33F_mutation Human genes 0.000 claims 1
- 230000004989 O-glycosylation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45654703P | 2003-03-20 | 2003-03-20 | |
| US60/456,547 | 2003-03-20 | ||
| US47970803P | 2003-06-19 | 2003-06-19 | |
| US60/479,708 | 2003-06-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504332A Division JP4847856B2 (ja) | 2003-03-20 | 2004-03-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012095641A JP2012095641A (ja) | 2012-05-24 |
| JP2012095641A5 true JP2012095641A5 (https=) | 2012-10-11 |
| JP2012095641A6 JP2012095641A6 (ja) | 2018-11-01 |
Family
ID=33032721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504332A Expired - Fee Related JP4847856B2 (ja) | 2003-03-20 | 2004-03-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
| JP2011160400A Pending JP2012095641A (ja) | 2003-03-20 | 2011-07-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504332A Expired - Fee Related JP4847856B2 (ja) | 2003-03-20 | 2004-03-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7771996B2 (https=) |
| EP (2) | EP2085470B1 (https=) |
| JP (2) | JP4847856B2 (https=) |
| AT (1) | ATE431403T1 (https=) |
| AU (2) | AU2004221761B2 (https=) |
| CA (1) | CA2519873C (https=) |
| DE (1) | DE602004021099D1 (https=) |
| DK (2) | DK1608745T3 (https=) |
| ES (2) | ES2327044T3 (https=) |
| WO (1) | WO2004083361A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| SI1499719T1 (sl) * | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
| DK1608745T3 (da) | 2003-03-20 | 2009-06-15 | Bayer Healthcare Llc | FVII eller FVIIa-Varianter |
| NZ573412A (en) | 2003-06-19 | 2010-09-30 | Maxygen Holdings Ltd | Factor VII or VIIa Gla domain variants |
| ATE469216T1 (de) | 2004-08-17 | 2010-06-15 | Csl Behring Gmbh | Modifizierte vitamin-k-abhängige polypeptide |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| ES2397851T3 (es) | 2005-07-13 | 2013-03-11 | Novo Nordisk Health Care Ag | Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas |
| JP5894722B2 (ja) | 2005-09-01 | 2016-03-30 | ノボ ノルディスク ヘルス ケア アーゲー | 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製 |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| ES2399138T3 (es) * | 2006-03-16 | 2013-03-26 | Stellaris Pharmaceuticals Aps | Tratamiento local con factor VII |
| WO2008025856A2 (en) | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| BRPI0810172A2 (pt) * | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| AU2013204377B2 (en) * | 2007-04-13 | 2015-07-16 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| CA3185756A1 (en) | 2012-12-24 | 2014-07-03 | Coagulant Therapeutics Corporation | Short-acting factor vii polypeptides |
| WO2019067766A1 (en) | 2017-09-27 | 2019-04-04 | Sigilon Therapeutics, Inc. | METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS |
| IL312315A (en) | 2018-04-04 | 2024-06-01 | Sigilon Therapeutics Inc | Implantable particles and related methods |
| WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| WO2021030787A1 (en) | 2019-08-15 | 2021-02-18 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| JP2025534667A (ja) | 2022-10-11 | 2025-10-17 | シギロン セラピューティクス， インコーポレイテッド | 疾患治療のための改変細胞及び移植可能エレメント |
| EP4602155A1 (en) | 2022-10-11 | 2025-08-20 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5180583A (en) | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5258288A (en) | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| FI882746L (fi) | 1987-06-12 | 1988-12-13 | Hoechst Japan | Hybridprotein c och foerfarande foer dess framstaellning. |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5648254A (en) | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5041376A (en) | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5093317A (en) | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5225537A (en) | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| ES2052368T3 (es) | 1990-01-26 | 1994-07-01 | Immuno Ag | Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso. |
| JP3330932B2 (ja) | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5531916A (en) | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
| JP4236698B2 (ja) | 1990-11-26 | 2009-03-11 | ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー | 宿主細胞でのｐａｃｅの発現およびその使用法 |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5817788A (en) | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| EP1479395A1 (en) | 1991-02-28 | 2004-11-24 | Novo Nordisk A/S | Modified factor VII |
| US5504064A (en) | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| AU703110B2 (en) | 1993-05-21 | 1999-03-18 | Novo Nordisk A/S | Modified factor VII |
| DE19531637A1 (de) | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| EP0946715B1 (en) | 1996-11-08 | 2006-03-29 | Oklahoma Medical Research Foundation | Use of a modified protein c |
| US5837843A (en) | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| BR9806793A (pt) * | 1997-01-22 | 2000-05-16 | Univ Texas | Processos e composições de fator tissular para coagulação e tratamento de tumores. |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| WO1998035026A1 (en) | 1997-02-06 | 1998-08-13 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| AU8101698A (en) | 1997-07-18 | 1999-02-10 | Novo Nordisk A/S | Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway |
| WO2001082943A2 (en) * | 2000-05-03 | 2001-11-08 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor vii |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| WO1999055377A2 (en) | 1998-04-28 | 1999-11-04 | Applied Research Systems Ars Holding N.V. | Polyol-ifn-beta conjugates |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| ATE390441T1 (de) | 1998-10-30 | 2008-04-15 | Novozymes As | Niedrigallergene proteinvarianten |
| DE69936351T2 (de) | 1998-10-30 | 2008-02-21 | Novozymes A/S | Glykosylierte proteine mit reduzierter allergenität |
| ATE408020T1 (de) | 1998-11-06 | 2008-09-15 | Novo Nordisk Healthcare Ag | Verfahren zur herstellung von faktor vii |
| AU3629800A (en) | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| DE60143292D1 (de) | 2000-05-03 | 2010-12-02 | Novo Nordisk Healthcare Ag | Varianten des menschlichen Koagulationsfaktors VII |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7160540B2 (en) | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| MXPA03001984A (es) | 2000-09-13 | 2003-08-29 | Novo Nordisk Healthcare Ag | Variantes de factor vii de coagulacion humano. |
| AU8755001A (en) * | 2000-09-13 | 2002-03-26 | Novo Nordisk As | Human coagulation factor vii variants |
| EP1325127B1 (en) | 2000-10-02 | 2009-03-11 | Novo Nordisk Health Care AG | Method for the production of vitamin k-dependent proteins |
| AU2002218029A1 (en) | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| MXPA03008590A (es) | 2001-03-22 | 2003-12-08 | Novo Nordisk Healthcare Ag | Derivados del factor vii de coagulacion. |
| BR0212818A (pt) | 2001-09-27 | 2004-10-05 | Novo Nordisk Healthcare Ag | Polipeptìdeo de fator vii, construção de polionucletìdeo, célula hospedeira, animal transgênico, planta transgênica, método para produzir o polipeptìdeo de fator vii composição farmacêutica, uso de um polipeptìdeo de fator vii, e, método para o tratamento de distúrbios do sangramento em um sujeito ou para o aprimoramento do sistema hemostático normal |
| JP2005512524A (ja) | 2001-11-02 | 2005-05-12 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固第ｖｉｉ因子ポリペプチド |
| AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
| SI1499719T1 (sl) | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
| AU2003266931B2 (en) | 2002-09-30 | 2010-01-21 | Bayer Healthcare Llc | FVII or FVIIa variants having increased clotting activity |
| DK1608745T3 (da) | 2003-03-20 | 2009-06-15 | Bayer Healthcare Llc | FVII eller FVIIa-Varianter |
| NZ573412A (en) | 2003-06-19 | 2010-09-30 | Maxygen Holdings Ltd | Factor VII or VIIa Gla domain variants |
| WO2005023308A1 (en) * | 2003-09-05 | 2005-03-17 | Maxygen Holdings Ltd. | Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
-
2004
- 2004-03-22 DK DK04722232T patent/DK1608745T3/da active
- 2004-03-22 AU AU2004221761A patent/AU2004221761B2/en not_active Ceased
- 2004-03-22 JP JP2006504332A patent/JP4847856B2/ja not_active Expired - Fee Related
- 2004-03-22 AT AT04722232T patent/ATE431403T1/de not_active IP Right Cessation
- 2004-03-22 WO PCT/DK2004/000193 patent/WO2004083361A2/en not_active Ceased
- 2004-03-22 US US10/549,506 patent/US7771996B2/en not_active Expired - Fee Related
- 2004-03-22 DK DK09075170.2T patent/DK2085470T3/da active
- 2004-03-22 ES ES04722232T patent/ES2327044T3/es not_active Expired - Lifetime
- 2004-03-22 EP EP09075170A patent/EP2085470B1/en not_active Expired - Lifetime
- 2004-03-22 DE DE602004021099T patent/DE602004021099D1/de not_active Expired - Lifetime
- 2004-03-22 EP EP04722232A patent/EP1608745B1/en not_active Expired - Lifetime
- 2004-03-22 CA CA2519873A patent/CA2519873C/en not_active Expired - Fee Related
- 2004-03-22 ES ES09075170T patent/ES2386010T3/es not_active Expired - Lifetime
-
2010
- 2010-03-25 AU AU2010201201A patent/AU2010201201A1/en not_active Abandoned
- 2010-05-05 US US12/774,560 patent/US20100330669A1/en not_active Abandoned
-
2011
- 2011-07-22 JP JP2011160400A patent/JP2012095641A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012095641A5 (https=) | ||
| JP2006521098A5 (https=) | ||
| JP2012105650A5 (https=) | ||
| CA2519873A1 (en) | Fvii or fviia variants | |
| JP2006527982A5 (https=) | ||
| ES2556596T3 (es) | Polipéptidos de factor VII que se modifican y usos de los mismos | |
| JP2023123756A5 (https=) | ||
| RU2004134726A (ru) | Варианты полипептида фактора vii или viia | |
| JP2006517089A5 (https=) | ||
| JP6655536B2 (ja) | 補因子の非存在下で凝固活性を有する、及び／又は、第ｉｘ因子凝固活性が増加した第ｉｘ因子変異体、並びに、出血性疾患を処置するためのその使用 | |
| JP2014513952A5 (https=) | ||
| CA2989990C (en) | Long-acting coagulation factors and methods of producing same | |
| AU2016202829B2 (en) | Long-acting coagulation factors and methods of producing same | |
| PT2147096E (pt) | Polipéptidos do factor vii modificados e suas utilizações | |
| JP2011517942A5 (https=) | ||
| HRP20100264T1 (hr) | Varijante gla domene faktora vii ili viia | |
| KR20160002848A (ko) | 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법 | |
| WO2008151817A1 (en) | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders | |
| RU2013151875A (ru) | Модифицированная кислая альфа глюкозидаза с ускоренным процессингом | |
| RU2012110221A (ru) | Аптамеры к ингибитору пути тканевого фактора и их использование в качестве терапевтических агентов при нарушениях свертываемости | |
| JP2022517267A (ja) | 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター | |
| WO2007022784A2 (en) | Liquid factor vii composition | |
| JP2013538863A5 (https=) | ||
| WO2021030787A1 (en) | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment | |
| JP2021530524A (ja) | 発現が増強された組換えｆｖｉｉｉ変異体をコードするウイルスベクターを使用する血友病ａの遺伝子療法 |